Focuses on developing therapies for liver disease, neurological disorders, and other chronic conditions.
BioVie Inc., a clinical stage biopharmaceutical company headquartered in Carson City, Nevada, is dedicated to advancing the discovery, development, and commercialization of innovative therapies for chronic debilitating conditions across the United States.
Central to BioVie's robust pipeline is BIV201, which has successfully completed a Phase IIa clinical trial. This therapeutic candidate targets ascites, a complication of chronic liver cirrhosis, offering promise for patients in need of effective treatment options. Additionally, BioVie is progressing NE3107 through clinical trials, including a Phase III trial for mild to moderate Alzheimer's disease and a Phase 2 trial for Parkinson's disease. NE3107, a selective inhibitor of inflammatory extracellular single-regulated kinase, also holds pottential applications in treating multiple myeloma and prostate cancer, currently in pre-clinical stages of development.
Formerly known as NanoAntibiotics, Inc., BioVie Inc. rebranded in July 2016 to reflect its expanded focus on pioneering therapies for chronic conditions. Since its inception in 2013, BioVie has been committed to leveraging scientific innovation to address unmet medical needs, driven by a mission to improve the quality of life for patients battling debilitating diseases. With a strategic emphasis on therapeutic advancement and rigorous clinical development, BioVie continues to chart new frontiers in biopharmaceutical research and healthcare innovation.